ARTICLE | Company News
FDA committee to discuss dapagliflozin
November 9, 2013 1:54 AM UTC
FDA's Endocrinologic and Metabolic Drugs Advisory Committee will meet on Dec. 12 to discuss a resubmitted NDA from Bristol-Myers Squibb Co. (NYSE:BMY) for Forxiga dapagliflozin to treat Type II diabet...